Real World Efficacy of Pembrolizumab of as a 1st Line Treatment in Metastatic Non-Small Cell Lung Cancer with PD-L1 High Expression

被引：0
|
作者：
Kasahara, K. [1 ]
Sone, T. [1 ]
Nishi, K. [2 ]
Shibata, K. [3 ]
Araya, T. [4 ]
Shirasaki, H. [5 ]
Yoneda, T. [6 ]
Kase, K. [7 ]
Nishikawa, S. [1 ]
Kimura, H. [1 ]
Tambo, Y. [1 ]
机构：
[1] Kanazawa Univ, Resp Med, Kanazawa, Ishikawa, Japan
[2] Ishikawa Prefectural Cent Hosp, Resp Med, Kanazawa, Ishikawa, Japan
[3] Kouseiren Takaoka Hosp, Med Oncol, Takaoka, Toyama, Japan
[4] Natl Hosp Org Kanazawa Med Ctr, Resp Med, Kanazawa, Ishikawa, Japan
[5] Fukui Ken Saiseikai Hosp, Resp Med, Fukui, Japan
[6] Komatsu Municipal Hosp, Resp Med, Komatsu, Japan
[7] Keiju Med Ctr, Resp Med, Nanao, Japan
来源：
JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 10期
关键词：
Pembrolizumab; 1st line treatment; PD-L1 high expression;
D O I：
10.1016/j.jtho.2019.08.953
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.04-50
引用
收藏
页码：S460 / S460
页数：1
相关论文
共 50 条
  • [41] Cost-Utility Analysis of Pembrolizumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small Cell Lung Cancer With Different PD-L1 Expression Levels
    Weng, Xiuhua
    Luo, Shaohong
    Lin, Shen
    Zhong, Lixian
    Li, Meiyue
    Xin, Rao
    Huang, Pinfang
    Xu, Xiongwei
    ONCOLOGY RESEARCH, 2020, 28 (02) : 117 - 125
  • [42] EFFICACY OF PD1/PD-L1 INHIBITORS VS CHEMOTHERAPY AS FIRST-LINE TREATMENT OF NON-SMALL CELL LUNG CANCER AMONG PATIENTS WITH DIFFERENT PD-L1 EXPRESSION LEVELS
    Lin, G.
    Lingohr-Smith, M.
    Deitelzweig, C.
    Lin, J.
    VALUE IN HEALTH, 2022, 25 (07) : S318 - S318
  • [43] The Efficacy of PD-1/PD-L1 Inhibitors in Patients with Liver Metastasis of Non-Small Cell Lung Cancer: A Real-World Study
    Xie, Mingying
    Li, Na
    Xu, Xiaoling
    Xu, Yanjun
    Li, Hui
    Zhu, Liang
    Sheng, Jiamin
    Zhou, Zichao
    Fan, Yun
    CANCERS, 2022, 14 (17)
  • [44] Non-Small Cell Lung Cancer, PD-L1, and the Pathologist
    Kerr, Keith M.
    Nicolson, Marianne C.
    ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2016, 140 (03) : 249 - 254
  • [45] Sugemalimab, a novel PD-L1 inhibitor for treatment of advanced or metastatic non-small cell lung cancer
    Sakamoto, Mandy
    Jimeno, Antonio
    DRUGS OF TODAY, 2023, 59 (03) : 169 - 177
  • [46] Association between metastatic sites and first-line pembrolizumab treatment outcome for advanced non-small cell lung cancer with high PD-L1 expression: a retrospective multicenter cohort study
    Kawachi, Hayato
    Tamiya, Motohiro
    Tamiya, Akihiro
    Ishii, Seigo
    Hirano, Katsuya
    Matsumoto, Hirotaka
    Fukuda, Yasushi
    Yokoyama, Toshihide
    Kominami, Ryota
    Fujimoto, Daichi
    Hosoya, Kazutaka
    Suzuki, Hidekazu
    Hirashima, Tomonori
    Kanazu, Masaki
    Sawa, Nobuhiko
    Uchida, Junji
    Morita, Mitsunori
    Makio, Takeshi
    Hara, Satoshi
    Kumagai, Toru
    INVESTIGATIONAL NEW DRUGS, 2020, 38 (01) : 211 - 218
  • [47] Real-world PD-L1 testing and distribution of PD-L1 tumor expression by immunohistochemistry assay type among patients with metastatic non-small cell lung cancer in the United States
    Velcheti, Vamsidhar
    Patwardhan, Pallavi D.
    Liu, Frank Xiaoqing
    Chen, Xin
    Cao, Xiting
    Burke, Thomas
    PLOS ONE, 2018, 13 (11):
  • [48] Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression
    Aguilar, E. J.
    Ricciuti, B.
    Gainor, J. F.
    Kehl, K. L.
    Kravets, S.
    Dahlberg, S.
    Nishino, M.
    Sholl, L. M.
    Adeni, A.
    Subegdjo, S.
    Khosrowjerdi, S.
    Peterson, R. M.
    Digumarthy, S.
    Liu, C.
    Sauter, J.
    Rizvi, H.
    Arbour, K. C.
    Carter, B. W.
    Heymach, J. V.
    Altan, M.
    Hellmann, M. D.
    Awad, M. M.
    ANNALS OF ONCOLOGY, 2019, 30 (10) : 1653 - 1659
  • [49] Real-world prospective data of small biopsy samples for tumor PD-L1 expression in non-small cell lung cancer
    Morikawa, K.
    Tsunoda, A.
    Inoue, T.
    Mineshita, M.
    ANNALS OF ONCOLOGY, 2018, 29
  • [50] Real-world efficacy and safety of anlotinib in combination with PD-1/PD-L1 inhibitors as first-line or second-line treatment in advanced non-small cell lung cancer
    Wang, Q.
    Ma, C.
    Wang, T.
    Chen, G.
    Wang, H.
    Mei, J.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1063 - S1063
12345